FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions
PR Newswire•16/11/2026•09:05 ET
0
Key Highlights
- ➤FDA clears MiniMed Fit, the company’s first tubeless insulin pump.
- ➤MiniMed Fit offers up to seven days’ wear and 300-unit insulin capacity.
- ➤U.S. phased rollout expected in spring 2027 after fiscal Q4 2027 early access.
- ➤MiniMed plans significant manufacturing-capacity expansion as commercialization progresses.
- ➤SmartGuard automation adjusts insulin delivery and delivers correction doses every five minutes.
Expert Statements
Que Dallara, Chief executive officer of MiniMed
“People with diabetes shouldn’t have to choose between the freedom of tubeless wear and the health outcomes they deserve.”
Que Dallara, Chief executive officer of MiniMed
“MiniMed Fit™ brings the technology people trust from MiniMed into a tubeless design that fits their lives.”
Que Dallara, Chief executive officer of MiniMed
“Clearing FDA ahead of schedule is more proof we’re executing our strategy.”
Que Dallara, Chief executive officer of MiniMed
“It puts MiniMed Fit in U.S. customers’ hands sooner, and the pharmacy channel makes it easier to get.”
FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions PR Newswire
The only tubeless pump with no charging or cartridge changes for up to seven days, combined with a 300-unit insulin capacity and advanced insulin automation
Get started
Create a free account to read the full story.
